Heart disease (especially myocardial infarction (MI)) and cancer are major causes of death.
Recently, aptasensors with the applying of different nanostructures have been able to …

Background The hepatocellular carcinoma is one of the most common malignant tumors and
carries a poor survival rate. The management of patients at risk for developing HCC remains …

With the global pandemic of hepatitis B and C infections, the incidence of Hepatocellular
carcinoma (HCC) is rapidly increasing world wide. We identified glypican-3 (GPC3), a novel …

Mortality due to hepatocellular carcinoma (HCC) has not improved over the last 20 years.
This is in part due to the poor performance of available tumor markers leading to delays in …

Background Intrahepatic recurrence is a significant problem for patients who have
undergone a hepatic resection for hepatocellular carcinoma (HCC). The objective of the …

Background: The effectiveness of tumor markers in evaluating outcomes of patients with
hepatocellular carcinoma (HCC) remains to be clarified. Summary: The usefulness of the …

Abstract Background: Updated National Academy of Clinical Biochemistry Laboratory
Medicine Practice Guidelines for the use of tumor markers in the clinic have been …

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some
areas of the world. In most cases, HCC is diagnosed at a late stage. Therefore, the …

The prevalence of hepatocellular carcinoma (HCC) worldwide parallels that of persistent
infection with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV). According to …

Background Since atezolizumab plus bevacizumab (ATE+ BEV) regimen for patients with
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …